SCHEMBL276534

SCHEMBL276534

CCC(C(=O)O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.39
CHRM1 P11229 2/20 0.36
ADRA1A P35348 2/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA1 P00915 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2631146 1.00 CA2 (0.41) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL12891264 1.00 CA2 (0.41) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL4578586 0.81 CA2 (0.39) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL28651642 0.80 SLC1A3 (0.36) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL9519201 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL17231916 0.79 CHRM1 (0.50) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL10925798 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL15821811 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL1966037 0.79 CHRM1 (0.50) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL28678611 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3088955-B1 RESIST COMPOSITION AND PATTERNING PROCESS SHINETSU CHEMICAL CO (JP) 2020-06-03 EP claimed
EP-1747183-B1 METHOD OF PREPARING ALKOXYLATION CATALYSTS AND THEIR USE IN ALKOXYLATION PROCESSES HARCROS CHEMICALS INC (US) 2018-06-06 EP claimed
EP-3032333-B1 SHRINK MATERIAL AND PATTERN FORMING PROCESS SHINETSU CHEMICAL CO (JP) 2017-05-24 EP claimed
EP-3032332-B1 SHRINK MATERIAL AND PATTERN FORMING PROCESS SHINETSU CHEMICAL CO (JP) 2017-04-05 EP claimed
EP-0522465-B1 A process for the preparation of an alkyl vinyl ether/maleic anhydride copolymer DAICEL CHEM (JP) 1997-04-16 EP claimed
JP-57085348-A None JP disclosed
US-11813306-B2 Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders NOVARTIS AG (CH) 2023-11-14 US disclosed
US-20230272239-A1 LIQUID COMPOSITION, LIQUID COMPOSITION FOR INKJET DISCHARGING, DEVICE FOR MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, METHOD OF MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, AND ELECTROCHEMICAL DEVICE RICOH COMPANY, LTD. (JP) 2023-08-31 US disclosed
EP-4235833-A1 LIQUID COMPOSITION, LIQUID COMPOSITION FOR INKJET DISCHARGING, DEVICE FOR MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, METHOD OF MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, AND ELECTROCHEMICAL DEVICE Ricoh Company, Ltd. (JP) 2023-08-30 EP disclosed
CN-116615411-A Process for producing peptide compound containing N-substituted amino acid residue 中外制药株式会社 2023-08-18 CN disclosed
CN-115666494-A Encapsulated compositions comprising core-shell microcapsules and methods of making the same 奇华顿股份有限公司 2023-01-31 CN disclosed
CN-115297858-A Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using same 赛特瑞恩股份有限公司 2022-11-04 CN disclosed
EP-0833879-A1 VAPOR PHASE COMBUSTION METHOD AND COMPOSITIONS II ORR, William C. (US) 1998-04-08 EP disclosed
EP-0763079-A1 VAPOR PHASE COMBUSTION METHODS AND COMPOSITIONS ORR, William C. (US) 1997-03-19 EP disclosed
WO-1996040844-A1 VAPOR PHASE COMBUSTION METHOD AND COMPOSITIONS II ORR WILLIAM C (US) 1996-12-19 WO disclosed
WO-1995033022-A1 VAPOR PHASE COMBUSTION METHODS AND COMPOSITIONS ORR WILLIAM C (US) 1995-12-07 WO disclosed
US-5401604-A Reaction product of polyepoxide, aromatic acid with phenolic hydroxy group, aromatic acid, quinone diazide with sulfonyl group, photoresists NIPPON PAINT CO., LTD. (JP) 1995-03-28 US disclosed
US-5374366-A Branched alkyl di-, tri- and tetraesters; machine oil miscible with hydrofluoroalkane refrigerants; high viscosity index; low pour point; heat, weather and hydrolysis resistance SANKEN CHEMICAL CO., LTD. (JP) 1994-12-20 US disclosed
EP-0608894-A1 Positive-type photosensitive resin compositions Nippon Paint Co., Ltd. (JP) 1994-08-03 EP disclosed
JP-S5785348-A OPTICAL ACTIVE N-BENZYL ACETAMIDE DERIVATIVE, ITS PREPARATION, AND HERBICIDE CONTAINING IT AS ACTIVE INGREDIENT SUMITOMO CHEM CO LTD 1982-05-28 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11813306-B2 Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders PCSK9, PCSK7, PCSK6 CA2 3259/4885MAPK1 1881/4885TSHR 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.